Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atai Beckley N.V.ATAI · Entity 72536 | Chief Financial Officer | March 14, 2023 | March 16, 2023 |
| CalciMedica, Inc.CALC · Entity 7804 | Chief Financial Officer | September 24, 2026 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atai Beckley N.V.
Report date March 14, 2023 · Filed March 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2033-03-14 | Direct | 600,000 |
Reported balance
After 2023-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-14 · Grant · Acquired 600,000 · Balance 600,000 F1: The stock option shall vest as to 25% of the underlying shares on March 14, 2024, and in 36 substantially equal monthly installments thereafter. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 350,000 |
Reported balance
After 2023-03-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-14 · Grant · Acquired 350,000 · Balance 350,000 F2: Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest as to 25% of the underlying shares on March 14, 2024, and in 36 substantially equal monthly installments thereafter.
F2: Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date.
CalciMedica, Inc.
Report date September 24, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2036-09-23 | Direct | 190,000 |
Reported balance
After 2026-09-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-24 · Grant · Acquired 190,000 · Balance 190,000 F1: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 28, 2026 20:27 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001942596-26-000003 · form4-09282026_080935.xml · derivative · entry 1 Bardin Stephen · CIK 0001942596 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2036-09-23 F1 · derivative.exercise_date: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period. Read SEC document |
| June 26, 2025 Filed Jun 26, 2025 22:30 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 2,000 | $1.50 | $3,005.00 |
DisclosureSEC source: 0001415889-25-018309 · form4-06262025_100618.xml · nonDerivative · entry 1 Bardin Stephen · CIK 0001942596 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 3,000 F1 · price: The weighted average purchase price for the transaction reported was $1.5025, and the range of prices were between $1.45 and $1.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · balance_after: Includes 1,000 shares held by The Bardin Family Trust dated June 4, 2024 (the "Trust") which were inadvertently reported as directly owned on the Form 4 filed with the SEC on June 3, 2025. F3 · ownership.nature: By The Bardin Family Trust dated June 4, 2024. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 22:30 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-018309 · form4-06262025_100618.xml · derivative · entry 3 Bardin Stephen · CIK 0001942596 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-04-22 F5 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. F6 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 21:10 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,000 | $1.69 | $1,690.00 |
DisclosureSEC source: 0001415889-25-015421 · form4-06032025_050601.xml · nonDerivative · entry 1 Bardin Stephen · CIK 0001942596 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,000 Read SEC document |
| April 23, 2025 Filed Apr 25, 2025 20:35 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-011365 · form4-04252025_080459.xml · derivative · entry 1 Bardin Stephen · CIK 0001942596 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2035-04-22 F1 · derivative.exercise_date: Beginning March 26, 2025, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period. Read SEC document |
| April 05, 2025 Filed Apr 8, 2026 01:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 67,728 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001942596-26-000002 · form4-04072026_090411.xml · derivative · entry 1 Bardin Stephen · CIK 0001942596 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,728 Underlying: Common Stock · 67,728 shares Expires 2036-04-04 F1 · derivative.exercise_date: Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:23 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantRestricted Stock Unit · Derivative | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008781 · doc4.xml · derivative · entry 2 Bardin Stephen · CIK 0001942596 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Shares · 350,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:23 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 600,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0000899243-23-008781 · doc4.xml · derivative · entry 1 Bardin Stephen · CIK 0001942596 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Shares · 600,000 shares Expires 2033-03-14 F1 · derivative.exercise_date: The stock option shall vest as to 25% of the underlying shares on March 14, 2024, and in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.